In a recent groundbreaking study by atai Life Sciences and Beckley Psytech, the innovative treatment BPL-003 has shown promising results for individuals suffering from moderate to severe alcohol use disorder (AUD). This synthetic intranasal formulation of 5-MeO-DMT benzoate was administered in a single dose alongside relapse prevention cognitive behavioral therapy, leading to significant reductions in alcohol consumption and an increase in abstinent days over a 12-week period.
The study reported that half of the participants achieved complete abstinence for the duration of the trial. Additionally, there were no serious adverse events, highlighting the treatment’s safety and tolerability. These findings not only underscore the potential of BPL-003 in treating AUD but also hint at its applicability in addressing other mental health disorders, with a Phase 2b trial for treatment-resistant depression on the horizon.
With an estimated 400 million people globally affected by AUD, current treatment options are insufficient. BPL-003 represents a significant advancement in the quest for more effective therapies. Beckley Psytech, supported by strategic investments from atai, continues to explore the therapeutic potentials of psychedelic medicines, anticipating further data in 2025.
